Triptans do not Increase Risk of Stroke in Migraine

Abstract

The incidence of stroke, cardiovascular events, and death among 63,575 patients with migraine was compared in those prescribed a triptan (13,664, 21.5%), non-triptan-treated, and matched nonmigraine control subjects (77,239) identified from the General Practice Research Database by researchers at the Institute of Neurology, University College, London, UK, and Pfizer Inc, New York, NY.

Keywords

• serious cardiovascular events
• triptans
• child-bearing age